Acorda is cutting jobs to save $21m annually and otherwise lowering expenses for a total of $60m in reduced costs in 2020 to focus on marketing Inbrija, but looming overhead is $345m in debt due in 2021. Meanwhile, ex-US partners and company buyers appear nowhere in sight.
Acorda Therapeutics Inc. is struggling to stay afloat as sales of Ampyra decline due to generic competition and while the company attempts to replace that revenue with its newly approved Inbrija. In the meantime, with $345m in debt due in two years, Acorda is reducing costs and cutting its workforce by 25% to lower its annual costs by $60m in 2020.
The company announced its restructuring plan after the stock market closed on 23 October and pre-reported its third quarter product...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
